Impact of ventricular assist device use on pediatric heart transplant waitlist mortality: Analysis of the scientific registry of transplant recipients database.
heart transplantation
outcomes
pediatrics
ventricular assist device
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
revised:
25
03
2024
received:
11
01
2024
accepted:
02
05
2024
medline:
20
5
2024
pubmed:
20
5
2024
entrez:
20
5
2024
Statut:
ppublish
Résumé
Children awaiting heart transplant (Tx) have a high risk of death due to donor organ scarcity. Historically, ventricular assist devices (VADs) reduced waitlist mortality, prompting increased VAD use. We sought to determine whether the VAD survival benefit persists in the current era. Using the Scientific Registry of Transplant Recipients, we identified patients listed for Tx between 3/22/2016 and 9/1/2020. We compared characteristics of VAD and non-VAD groups at Tx listing. Cox proportional hazards models were used to identify risk factors for 1-year waitlist mortality. Among 5054 patients, 764 (15%) had a VAD at Tx listing. The VAD group was older with more mechanical ventilation and renal impairment. Unadjusted waitlist mortality was similar between groups; the curves crossed ~90 days after listing (p = .55). In multivariable analysis, infant age (HR 2.77, 95%CI 2.13-3.60), Black race (HR 1.57, 95%CI 1.31-1.88), congenital heart disease (HR 1.23, 95%CI 1.04-1.46), renal impairment (HR 2.67, 95%CI 2.19-3.26), inotropes (HR 1.28, 95%CI 1.09-1.52), and mechanical ventilation (HR 2.23, 95%CI 1.84-2.70) were associated with 1-year waitlist mortality. VADs were not associated with mortality in the first 90 waitlist days but were protective for those waiting ≥90 days (HR 0.43, 95%CI 0.26-0.71). In the current era, VADs reduce waitlist mortality, but only for those waitlisted ≥90 days. The differential effect by race, size, and VAD type is less clear. These findings suggest that Tx listing without VAD may be reasonable if a short waitlist time is anticipated, but VADs may benefit those expected to wait >90 days.
Sections du résumé
BACKGROUND
BACKGROUND
Children awaiting heart transplant (Tx) have a high risk of death due to donor organ scarcity. Historically, ventricular assist devices (VADs) reduced waitlist mortality, prompting increased VAD use. We sought to determine whether the VAD survival benefit persists in the current era.
METHODS
METHODS
Using the Scientific Registry of Transplant Recipients, we identified patients listed for Tx between 3/22/2016 and 9/1/2020. We compared characteristics of VAD and non-VAD groups at Tx listing. Cox proportional hazards models were used to identify risk factors for 1-year waitlist mortality.
RESULTS
RESULTS
Among 5054 patients, 764 (15%) had a VAD at Tx listing. The VAD group was older with more mechanical ventilation and renal impairment. Unadjusted waitlist mortality was similar between groups; the curves crossed ~90 days after listing (p = .55). In multivariable analysis, infant age (HR 2.77, 95%CI 2.13-3.60), Black race (HR 1.57, 95%CI 1.31-1.88), congenital heart disease (HR 1.23, 95%CI 1.04-1.46), renal impairment (HR 2.67, 95%CI 2.19-3.26), inotropes (HR 1.28, 95%CI 1.09-1.52), and mechanical ventilation (HR 2.23, 95%CI 1.84-2.70) were associated with 1-year waitlist mortality. VADs were not associated with mortality in the first 90 waitlist days but were protective for those waiting ≥90 days (HR 0.43, 95%CI 0.26-0.71).
CONCLUSIONS
CONCLUSIONS
In the current era, VADs reduce waitlist mortality, but only for those waitlisted ≥90 days. The differential effect by race, size, and VAD type is less clear. These findings suggest that Tx listing without VAD may be reasonable if a short waitlist time is anticipated, but VADs may benefit those expected to wait >90 days.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14787Subventions
Organisme : NCATS NIH HHS
ID : UL1TR002378
Pays : United States
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Almond CSD, Thiagarajan RR, Piercey GE, et al. Waiting list mortality among children listed for heart transplantation in the United States. Circulation. 2009;119:717‐727.
Jeewa A, Manlhiot C, Kantor PF, Mital S, McCrindle BW, Dipchand AI. Risk factors for mortality or delisting of patients from the pediatric heart transplant waiting list. J Thorac Cardiovasc Surg. 2014;147:462‐468.
Rana A, Fraser CD, Scully BB, et al. Inferior outcomes on the waiting list in low‐volume pediatric heart transplant centers. Am J Transplant. 2017;17:1515‐1524.
Riggs KW, Zafar F, Lorts A, Villa CR, Bryant R 3rd, Morales DLS. Optimizing postcardiac transplantation outcomes in children with ventricular assist devices: how long should the bridge be? ASAIO J. 2020;66:787‐795.
Zafar F, Castleberry C, Khan MS, et al. Pediatric heart transplant waiting list mortality in the era of ventricular assist devices. J Heart Lung Transplant. 2015;34:82‐88.
Morales DLS, Adachi I, Peng DM, et al. Fourth annual pediatric interagency registry for mechanical circulatory support (Pedimacs) report. Ann Thorac Surg. 2020;110:1819‐1831.
Singh TP, Cherikh WS, Hsich E, et al. The international thoracic organ transplant registry of the International Society for Heart and Lung Transplantation: twenty‐fourth pediatric heart transplantation report – 2021; focus on recipient characteristics. J Heart Lung Transplant. 2021;40:1050‐1059.
Rossano JW, VanderPluym CJ, Peng DM, et al. Fifth annual pediatric interagency registry for mechanical circulatory support (Pedimacs) report. Ann Thorac Surg. 2021;112:1763‐1774.
Mokhayeri Y, Hashemi‐Nazari SS, Mansournia MA, Soori H, Khodakarim S. The association between physical activity and atrial fibrillation applying the Heaviside function in survival analysis: the multi‐ethnic study of atherosclerosis. Epidemiol Health. 2017;39:e2017024.
Law SP, Oron AP, Kemna MS, et al. Comparison of transplant waitlist outcomes for pediatric candidates supported by ventricular assist devices versus medical therapy. Pediatr Crit Care Med. 2018;19:442‐450.
Wehman B, Stafford KA, Bittle GJ, et al. Modern outcomes of mechanical circulatory support as a bridge to pediatric heart transplantation. Ann Thorac Surg. 2016;101:2321‐2327.
Kirk R, Dipchand AI, Davies RR, et al. ISHLT consensus statement on donor organ acceptability and management in pediatric heart transplantation. J Heart Lung Transplant. 2020;39:331‐341.
Denfield SW, Azeka E, Das B, et al. Pediatric cardiac waitlist mortality‐still too high. Pediatr Transplant. 2020;24:e13671.
Butto A, Teele SA, Sleeper LA, et al. The impact of pre‐implant illness severity on the outcomes of pediatric patients undergoing durable ventricular assist device. J Heart Lung Transplant. 2020;39:666‐674.
Adachi I, Zea‐Vera R, Tunuguntla H, et al. Centrifugal‐flow ventricular assist device support in children: a single‐center experience. J Thorac Cardiovasc Surg. 2019;157:1609‐1617.e2.
O'Connor MJ, Lorts A, Davies RR, et al. Early experience with the HeartMate 3 continuous‐flow ventricular assist device in pediatric patients and patients with congenital heart disease: a multicenter registry analysis. J Heart Lung Transplant. 2020;39:573‐579.
Peng DM, Koehl DA, Cantor RS, et al. Outcomes of children with congenital heart disease implanted with ventricular assist devices: an analysis of the pediatric interagency registry for mechanical circulatory support (Pedimacs). J Heart Lung Transplant. 2019;38:420‐430.
Bleiweis MS, Philip J, Peek GJ, et al. Palliation plus ventricular assist device insertion in 15 neonates and infants with functionally univentricular circulation. Ann Thorac Surg. 2022;114:1412‐1418.
Amdani S, Bhimani SA, Boyle G, et al. Racial and ethnic disparities persist in the current era of pediatric heart transplantation. J Card Fail. 2021;27:957‐964.